The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1541
Odactra - Sublingual Immunotherapy for House Dust Mite-Induced Allergic Rhinitis
The full article is available to subscribers Subscriber Login   

The FDA has approved Odactra (ALK), a sublingual allergen extract, for immunotherapy in adults 18-65 years old with house dust mite (HDM)-induced allergic rhinitis, with or without conjunctivitis. Odactra is the first sublingual allergen extract to be approved in the US for this indication. Three other sublingual allergen extracts were approved earlier (see Table 1).1

STANDARD TREATMENT — Oral second-generation H1-antihistamines are the preferred first-line treatment for relief of the itching, sneezing, and rhinorrhea that characterize mild to moderate allergic rhinitis. They are less effective for relief of nasal congestion. Intranasal corticosteroids are the most effective drugs available for prevention and relief of allergic rhinitis symptoms, including nasal congestion, and ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Odactra - Sublingual Immunotherapy for House Dust Mite-Induced Allergic Rhinitis
Article code: 1541c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian